Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Market Closed 04-17 16:00:00 EDT

1.27

+0.02

+1.60%

盘后1.24

-0.03-2.36%

19:42 EDT

High1.30	Low1.24	Vol62.04K
Open1.30	D1 Closing1.25	Amplitude5.06%
Mkt Cap45.58M	Tradable Cap34.59M	Total Shares35.89M
T/O78.66K	T/O Rate0.23%	Tradable Shares27.23M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":1.27,"timestamp":1744920000000,"preClose":1.25,"halted":0,"volume":62042,"hourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.27,"latestTime":"19:42 EDT","volume":1316,"amount":1640.4053,"timestamp":1744933366734},"delay":0,"floatShares":27234408,"shares":35887252,"eps":-2.035804,"marketStatus":"Market Closed","change":0.02,"latestTime":"04-17 16:00:00 EDT","open":1.3,"high":1.3032,"low":1.24,"amount":78663.52952340001,"amplitude":0.05056,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.035804,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.33,"preClose":1.25,"latestTime":"09:13 EDT","volume":18,"amount":23.6344014,"timestamp":1744895638131},"postHourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.27,"latestTime":"19:42 EDT","volume":1316,"amount":1640.4053,"timestamp":1744933366734},"volumeRatio":0.4752238932193068},"requestUrl":"/m/hq/s/IMRX","defaultTab":"news","newsList":[{"id":"2526547565","title":"Immuneering Price Target Maintained With a $12.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2526547565","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526547565?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 19:07","pubTimestamp":1744283220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 07:07 ET (11:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2521429117","title":"Immuneering Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2521429117","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521429117?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:53","pubTimestamp":1742817180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 07:53 ET (11:53 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2521610296","title":"Immuneering Corp. Reports Promising Cancer Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521610296","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521610296?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 11:51","pubTimestamp":1742615464,"startTime":"0","endTime":"0","summary":"Immuneering Corp. Class A ( ($IMRX) ) has released its Q4 earnings. Here is a breakdown of the information Immuneering Corp. Class A presented to i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immuneering-corp-reports-promising-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immuneering-corp-reports-promising-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMRX","BK4563","BK4539"],"gpt_icon":0},{"id":"2521541532","title":"Press Release: Immuneering Corporation Announces Grant of Inducement Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2521541532","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521541532?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 04:30","pubTimestamp":1742589000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., March 21, 2025  -- Immuneering Corporation , a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on March 20, 2025, that Igor Matushansky, M.D., Ph.D., was named Chief Medical Officer of the Company. In connection with the commencement of Dr. Matushanky's employment, on March 21, 2025, Dr. Matushanky was granted an option to purchase 118,000 shares of the Company's Class A common stock with a per share exercise price of $1.80, the closing trading price of the Company's Class A common stock on the Nasdaq Global Market on March 21, 2025. The stock option was granted pursuant to the Company's 2025 Employment Inducement Award Plan and was approved by the Company's Board of Directors. The stock option has a ten-year term and vests  25% on March 17, 2026 and the remaining 75% in substantially equal monthly installments over the three years thereafter, such that the sto","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2521281353","title":"Immuneering Price Target Maintained With a $12.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2521281353","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521281353?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:07","pubTimestamp":1742562420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 09:07 ET (13:07 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2521037934","title":"North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2521037934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521037934?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 18:02","pubTimestamp":1742551320,"startTime":"0","endTime":"0","summary":"The euphoria from the Federal Reserve's policy meeting didn't last long.Stock futures were lower Friday as attention shifted from the Fed to the prospect of further tariffs.Trump said in a social media post that the planned imposition of reciprocal tariffs on April 2 would be \"Liberation Day\" in the U.S.\"We maintain our view that the FOMC outcome was effectively a one-day move, with minimal legacy in terms of immediate direction. That said, we also view the FOMC outcome as a whole as nodding towards dovishness, but with numerous caveats,\" ING said.Quantum-computing stocks  are likely to be in focus after suffering steep falls on Thursday as investors appeared unimpressed by their contributions to Nvidia's Quantum Day at its GTC developers' event.The market also faces a test as an estimated $4.5 trillion in options contracts expire, which could increase volatility.FedEx fell 5.1% off hours after it cut its outlook for the year.Lennar management warned investors of a weak housing market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATXI","SMXT","US5Y.BOND","ADVM","CCL","NVDL","US3Y.BOND","IMNM","JVA","NVD3.UK","PRPH","PURE","CKPT","US6M.BOND","NVD2.UK","NVDX","BOLD","OLMA","2NVD.UK","FBLG","NVDA","NVDS.UK","NVDY","FBRX","MPU","SGMA","US10Y.BOND","ZBIO","IRD","NVDD","GORV","DXYN","NGNE","IMRX","US2Y.BOND","US12M.BOND","BPTH","SNVD.UK","XOMA","US7Y.BOND","NVDS","AFG","3NVD.UK","NVDU","USAU","US30Y.BOND","ET","DM","NVIW.SI"],"gpt_icon":1},{"id":"2521402491","title":"BRIEF-Immuneering Corporation Q4 Net Income USD 18.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521402491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521402491?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:54","pubTimestamp":1742504046,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneering Corporation Q4 Net Income USD 18.1 MillionMarch 20 (Reuters) - Immuneering Corp IMRX.O:IMMUNEERING CORPORATION Q4 NET INCOME USD -18.1 MILLIONIMMUNEERING CORPORATION Q4 EPS USD -0.58Source text: ID:nGNX3JlvlkFurther company coverage: IMRX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nPLX1461D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4539","BK4563"],"gpt_icon":0},{"id":"2521496021","title":"Immuneering Q4 EPS $(0.58) Misses $(0.46) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496021","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496021?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:19","pubTimestamp":1742501969,"startTime":"0","endTime":"0","summary":"Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 11.54 percent decrease over losses of $(0.52) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44425416/immuneering-q4-eps-0-58-misses-0-46-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Immuneering Q4 EPS $(0.58) Misses $(0.46) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2521349613","title":"Immuneering Corp: Expects Its Cash Runway to Be Sufficient to Fund Operations Into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2521349613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521349613?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:05","pubTimestamp":1742501101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUAB0MDTF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMRX","BK4563","BK4539"],"gpt_icon":0},{"id":"2521496920","title":"Immuneering Corporation Q4 EPS USD -0.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496920?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:05","pubTimestamp":1742501101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nPLX1461D4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","BK4563","IMRX"],"gpt_icon":0},{"id":"2520327244","title":"Immuneering Names DR. Igor Matushansky as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520327244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520327244?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:00","pubTimestamp":1742468401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUAB58JL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","IMRX","BK4563"],"gpt_icon":0},{"id":"2520743752","title":"Press Release: Immuneering Names Dr. Igor Matushansky as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520743752","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520743752?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:00","pubTimestamp":1742468400,"startTime":"0","endTime":"0","summary":"Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients. Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025. Dr. Matushansky was previously Chief Medical Officer at Sail Biomedicines , where he built and led the clinical/medical, translational, operational, and regulatory functions. Prior to that, he was SVP and Global Head of Oncology Development at Ipsen Pharmaceuticals, where, amongst many programs, he oversaw the completion of NAPOLI-3 leading to the approval of NALIRIFOX for first-line pancreatic cancer. Dr. Matushansky also served as Chief Medical Officer and Global Head of Research and Development at Hookipa Pharma, where he was responsibl","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"2520609467","title":"Immuneering (NASDAQ:IMRX) Will Have To Spend Its Cash Wisely","url":"https://stock-news.laohu8.com/highlight/detail?id=2520609467","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520609467?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:37","pubTimestamp":1742301476,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imrx/immuneering/news/immuneering-nasdaqimrx-will-have-to-spend-its-cash-wisely","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["USJW.SI","LU2095319765.USD","LU2210150020.SGD",".IXIC","BK4539","MNQmain","BK4139","QID","NDAQ","BK4585","QLD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","TQQQ","BK4112","IE00B64PRP62.GBP","BK4563","TSYW.SI","LU2210149790.SGD","USAW.SI","SQQQ","PSQ","NQmain","IMRX","IE00BGHQF748.EUR","NVIW.SI","BK4588"],"gpt_icon":1},{"id":"2517043745","title":"Immuneering management to meet with Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517043745","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517043745?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 23:55","pubTimestamp":1741362947,"startTime":"0","endTime":"0","summary":"Meetings to be held March 10-11 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-management-to-meet-with-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-management-to-meet-with-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX","BK4127","BK4539","BK4563","BK4139","OPY"],"gpt_icon":0},{"id":"2517990373","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517990373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517990373?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 19:00","pubTimestamp":1741172400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Abercrombie & Fitch                              4Q      3.54   7:30 AM. ·ACRES Cmmcl Rlty                                 4Q       .36   4:15 PM. ·Descartes Sys Gp                                4Q       .43   5:00 PM. ·Dine Brands Global                               4Q      1.34   7:00 AM. ·Foot Locker Inc.                                  4Q       .72   6:45 AM. ·Forge Global Hldgs                              4Q      (.09)  4:10 PM. ·Global Ship Lease                                4Q      2.31   8:00 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KR","SNBR","ZYME","HIPO","DESP","HDSN","MRVL","BF.B","BF.A","OCGN","FL","LPSN","SVCO","VEEV","CAPR","ALNT","ALTG","RSKD","SGHT","PAM","CRVS","TCRX","ATER","ARCT","ATXS","CNQ","FSM","ZS","ALGS","QNRX","FRGE","BALY","TREE","AKA","IMRX","LB","GAP","AMTX","DIN","EYPT","FDUS","ARQ","DOMO","MRX","GRND","AVGO","SKLZ","CRMT","ECOR"],"gpt_icon":1},{"id":"2509207352","title":"Immuneering Price Target Maintained With a $12.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2509207352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509207352?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 02:09","pubTimestamp":1738865340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 06, 2025 13:09 ET (18:09 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2509076277","title":"Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Palatin Technologies (PTN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509076277","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509076277?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 23:10","pubTimestamp":1738854612,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immuneering (IMRX – Research Report) and Palatin Tec...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-and-palatin-technologies-ptn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-and-palatin-technologies-ptn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4539","BK4563","HCSG","BK4139","IMRX","PTN"],"gpt_icon":0},{"id":"2509822293","title":"Immuneering Corp - to Sponsor Studies, Regeneron to Provide Libtayo","url":"https://stock-news.laohu8.com/highlight/detail?id=2509822293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509822293?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 20:00","pubTimestamp":1738843201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6CCNVV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2509222318","title":"Immuneering Announces Clinical Supply Agreement With Regeneron Pharmaceuticals to Evaluate Imm-1-104 in Combination With Libtayo® (Cemiplimab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509222318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509222318?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 20:00","pubTimestamp":1738843201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6CCNVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4539","BK4139","IMRX"],"gpt_icon":0},{"id":"2509422789","title":"Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509422789","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509422789?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 20:00","pubTimestamp":1738843200,"startTime":"0","endTime":"0","summary":"- Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports dual-t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/06/3021891/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Regeneron-Pharmaceuticals-to-Evaluate-IMM-1-104-in-Combination-with-Libtayo-cemiplimab.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU0882574055.USD","LU0289739699.SGD","LU2362540622.SGD","LU0823416689.USD","LU2362541273.HKD","LU2237438978.USD","LU0109394709.USD","BK4539","IMRX","LU0114720955.EUR","LU2468319806.SGD","LU2362541513.USD","LU1974910355.USD","REGN","LU0320765992.SGD","BK4588","LU2089984988.USD","BK4563","LU0058720904.USD","LU2023250504.SGD","BK4585","BK4139","LU1917777945.USD","LU0889565916.HKD","LU2106854487.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":0.0242},{"period":"1month","weight":-0.244},{"period":"3month","weight":-0.3713},{"period":"6month","weight":-0.433},{"period":"1year","weight":-0.3172},{"period":"ytd","weight":-0.4227}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.209299},{"month":2,"riseRate":0.5,"avgChangeRate":-0.044801},{"month":3,"riseRate":0.25,"avgChangeRate":0.059789},{"month":4,"riseRate":0.25,"avgChangeRate":-0.193543},{"month":5,"riseRate":0,"avgChangeRate":-0.137963},{"month":6,"riseRate":0.666667,"avgChangeRate":0.145613},{"month":7,"riseRate":0.666667,"avgChangeRate":0.029987},{"month":8,"riseRate":0.25,"avgChangeRate":0.029018},{"month":9,"riseRate":0.75,"avgChangeRate":0.686735},{"month":10,"riseRate":0.25,"avgChangeRate":-0.087438},{"month":11,"riseRate":0.25,"avgChangeRate":-0.159888},{"month":12,"riseRate":0.5,"avgChangeRate":-0.091275}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}